Eisai and partner Biogen say their Alzheimer’s drug has significantly slowed the disease, making it the first medicine to clearly blunt the progression of the most common type of dementia in a definitive, large-scale trial.
Lecanemab reduced the pace of cognitive decline in people with early disease by 27 per cent over 18 months when compared with a placebo, meeting the main goal of the trial, the companies said in a statement. The benefit came with side effects, including brain swelling and bleeding, though severe cases were rare.
